Posted on by admin

Congenital Adrenal Hyperplasia Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma

Congenital Adrenal Hyperplasia Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma
The Congenital Adrenal Hyperplasia Market size was valued approximately USD 21 million in 2021 and the report offers an in-depth understanding of the Congenital Adrenal Hyperplasia, historical and forecasted epidemiology as well as the Congenital Adrenal Hyperplasia market trends in the 7MM.

DelveInsight’s “Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Congenital Adrenal Hyperplasia, historical and forecasted epidemiology as well as the Congenital Adrenal Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Congenital Adrenal Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congenital Adrenal Hyperplasia Market Forecast

 

Some of the key facts of the Congenital Adrenal Hyperplasia Market Report: 

  • The Congenital Adrenal Hyperplasia market size was valued approximately USD 21 million in 2021 and  is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In October 2023, Neurocrine Biosciences has announced favorable top-line outcomes from the Phase III CAHtalyst Pediatric trial of crinecerfont, intended for managing congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency. This global, registrational study evaluated the tolerability, effectiveness, and safety of crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist, in pediatric and adolescent populations.

  • As per the National Organization for Rare Disorders (2023), the prevalent form of CAH, known as 21 hydroxylase deficiency, impacts roughly 1 in 10,000 to 1 in 15,000 individuals in both the United States and Europe.

  • According to Momodu et al. (2023), congenital adrenal hyperplasia primarily arises due to mutations or deletions within the CYP21A gene. While the estimated prevalence is approximately one case per 60 individuals in the general population, it escalates to one in three within specific genetically isolated communities characterized by a smaller gene pool.

  • Key Congenital Adrenal Hyperplasia Companies: Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics Pharmaceuticals Inc., Spruce Biosciences, Neurocrine Biosciences, Millendo Therapeutics, Inc, Adrenas Therapeutics Inc, Diurnal Limited, Novartis, and others

  • Key Congenital Adrenal Hyperplasia Therapies: Tildacerfont, NBI-74788, BBP-631, CRN04894, SPR001, Crinecerfont, ATR-101, AAV BBP-631, Chronocort, Osilodrostat, and others

  • The Congenital Adrenal Hyperplasia epidemiology based on gender analyzed that no gender related difference was observed in case of Congenital Adrenal Hyperplasia

  • The Congenital Adrenal Hyperplasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congenital Adrenal Hyperplasia pipeline products will significantly revolutionize the Congenital Adrenal Hyperplasia market dynamics.

 

Congenital Adrenal Hyperplasia Overview

Congenital Adrenal Hyperplasia (CAH) is a group of inherited genetic disorders that affect the adrenal glands, which are small glands located on top of the kidneys. These glands produce hormones that regulate various bodily functions, including metabolism, stress response, and sexual development.

 

Get a Free sample for the Congenital Adrenal Hyperplasia Market Report:

https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market

 

Congenital Adrenal Hyperplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Congenital Adrenal Hyperplasia Epidemiology Segmentation:

The Congenital Adrenal Hyperplasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Congenital Adrenal Hyperplasia

  • Prevalent Cases of Congenital Adrenal Hyperplasia by severity

  • Gender-specific Prevalence of Congenital Adrenal Hyperplasia

  • Diagnosed Cases of Episodic and Chronic Congenital Adrenal Hyperplasia

 

Download the report to understand which factors are driving Congenital Adrenal Hyperplasia epidemiology trends @ Congenital Adrenal Hyperplasia Epidemiology Forecast

 

Congenital Adrenal Hyperplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Adrenal Hyperplasia market or expected to get launched during the study period. The analysis covers Congenital Adrenal Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congenital Adrenal Hyperplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Congenital Adrenal Hyperplasia Therapies and Key Companies

  • Tildacerfont: Spruce Biosciences

  • NBI-74788: Neurocrine Bioscience

  • BBP-631: BridgeBio Pharma

  • CRN04894: Crinetics Pharmaceuticals Inc.

  • SPR001: Spruce Biosciences

  • Crinecerfont: Neurocrine Biosciences

  • ATR-101: Millendo Therapeutics, Inc.

  • AAV BBP-631: Adrenas Therapeutics Inc

  • Chronocort: Diurnal Limited

  • Osilodrostat: Novartis

 

Discover more about therapies set to grab major Congenital Adrenal Hyperplasia market share @ Congenital Adrenal Hyperplasia Treatment Market

 

Scope of the Congenital Adrenal Hyperplasia Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Congenital Adrenal Hyperplasia Companies: Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics Pharmaceuticals Inc., Millendo Therapeutics, Inc, Adrenas Therapeutics Inc, Diurnal Limited, Novartis, and others

  • Key Congenital Adrenal Hyperplasia Therapies: Tildacerfont, NBI-74788, BBP-631, CRN04894, SPR001, Crinecerfont, ATR-101, AAV BBP-631, Chronocort, Osilodrostat, and others

  • Congenital Adrenal Hyperplasia Therapeutic Assessment: Congenital Adrenal Hyperplasia current marketed and Congenital Adrenal Hyperplasia emerging therapies

  • Congenital Adrenal Hyperplasia Market Dynamics: Congenital Adrenal Hyperplasia market drivers and Congenital Adrenal Hyperplasia market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Congenital Adrenal Hyperplasia Unmet Needs, KOL’s views, Analyst’s views, Congenital Adrenal Hyperplasia Market Access and Reimbursement 

 

To know more about Congenital Adrenal Hyperplasia companies working in the treatment market, visit @ Congenital Adrenal Hyperplasia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Congenital Adrenal Hyperplasia Market Report Introduction

2. Executive Summary for Congenital Adrenal Hyperplasia

3. SWOT analysis of Congenital Adrenal Hyperplasia

4. Congenital Adrenal Hyperplasia Patient Share (%) Overview at a Glance

5. Congenital Adrenal Hyperplasia Market Overview at a Glance

6. Congenital Adrenal Hyperplasia Disease Background and Overview

7. Congenital Adrenal Hyperplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Congenital Adrenal Hyperplasia 

9. Congenital Adrenal Hyperplasia Current Treatment and Medical Practices

10. Congenital Adrenal Hyperplasia Unmet Needs

11. Congenital Adrenal Hyperplasia Emerging Therapies

12. Congenital Adrenal Hyperplasia Market Outlook

13. Country-Wise Congenital Adrenal Hyperplasia Market Analysis (2020–2034)

14. Congenital Adrenal Hyperplasia Market Access and Reimbursement of Therapies

15. Congenital Adrenal Hyperplasia Market Drivers

16. Congenital Adrenal Hyperplasia Market Barriers

17.  Congenital Adrenal Hyperplasia Appendix

18. Congenital Adrenal Hyperplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/